Table 1 Baseline information of IgAN patients with stage 4 CKD
Parameters | Overall (n = 69) | Non-ESRD (n = 43) | ESRD (n = 26) | P |
|---|---|---|---|---|
Clinical findings | ||||
Age (y) | 43.0 (31.0–50.0) | 43.0 (31.0–57.0) | 38.0 (28.0–46.0) | 0.06 |
Gender, M (%) | 33 (47.8) | 20 (46.5) | 13 (50.0) | 0.78 |
BMI (kg/m2) | 24.9 (22.2–27.3) | 24.9 (22.5–27.8) | 24.8 (21.5–26.6) | 0.57 |
MAP (mmHg) | 102.7 (96.7-117.3) | 100.7 (96.0-112.0) | 110.3 (96.7-116.7) | 0.30 |
Hypertension, n (%) | 44 (63.8) | 29 (67.4) | 15 (57.7) | 0.41 |
Use of RASi, n (%) | 27 (39.1) | 19 (44.2) | 8 (30.8) | 0.27 |
Use of IS, n (%) | 0.37 | |||
Glucocorticoids | 14 (20.3) | 9 (20.9) | 2 (7.7) | Â |
Glucocorticoids + CTX | 18 (26.1) | 14 (32.6) | 6 (23.1) |  |
Glucocorticoids + HCQ | 1 (1.4) | 1 (2.3) | 0 (0.0) |  |
Glucocorticoids + Rituximab | 1 (1.4) | 0 (0.0) | 1 (3.8) |  |
Laboratory findings | ||||
Hb (g/L) | 111.0 (103.5–123.0) | 114.0 (103.0-125.0) | 109.0 (104.0-122.0) | 0.46 |
eGFR (ml/min/1.73m2) | 24.9 (20.7–26.4) | 25.3 (22.5–26.7) | 22.0 (19.9–26.1) | 0.07 |
24 h-UP (g/d) | 2.7 (1.5–4.3) | 2.5 (1.4–3.5) | 3.2 (2.2–4.7) | 0.07 |
URBC (/HPF) | 14.4 (5.0-55.5) | 11.7 (3.5–87.3) | 16.6 (6.0-42.1) | 0.73 |
UA (µmol/L) | 464.0 (413.0-518.5) | 464.0 (411.0-529.0) | 464.0 (416.5-503.3) | 0.90 |
PTH (pg/mL) | 75.2 (44.5–131.0) | 70.0 (43.2-128.3) | 84.0 (51.8-139.9) | 0.20 |
TC (mmol/L) | 5.2 (4.3–6.2) | 5.2 (4.2-6.0) | 5.6 (4.3-7.0) | 0.43 |
TG (mmol/L) | 1.8 (1.5–2.4) | 1.7 (1.3–2.4) | 1.9 (1.6–2.3) | 0.32 |
Serum IgA/C3 | 3.4 (2.6–4.8) | 3.4 (2.6–4.9) | 3.3 (2.6–4.8) | 0.90 |
Kidney morphology, n | Â | |||
Total glomeruli | 19 (14–26) | 19 (14–30) | 19 (14–22) | 0.49 |
Totally sclerotic glomeruli | 5 (2–10) | 2 (4–10) | 5 (1–10) | 0.87 |
Glomerular C3 deposition, n (%) | 0.004 | |||
C3 negative | 3 (4.3) | 3 (7.0) | 0 (0.0) | Â |
C3 1 + ~ 2+ | 24 (34.8) | 20 (46.5) | 4 (15.4) |  |
C3 3 + or higher | 42 (60.9) | 20 (46.5) | 22 (84.6) |  |
Glomerular C1q deposition, n (%) | < 0.001 | |||
C1q negative | 57 (82.6) | 41 (95.3) | 16 (61.5) | Â |
C1q positive | 12 (17.4) | 2 (4.7) | 10 (38.5) | Â |
Oxford Classification, n (%) | Â | |||
M1 | 67 (97.1) | 42 (97.7) | 25 (96.2) | 1.00 |
E1 | 63 (91.3) | 40 (93.0) | 23 (88.5) | 0.67 |
S1 | 42 (60.9) | 25 (58.1) | 17 (65.4) | 0.55 |
T (1/2) | 60 (87.0) | 36 (83.7) | 24 (92.3) | 0.47 |
T1 | 40 (58.0) | 27 (62.8) | 13 (50.0) | Â |
T2 | 20 (29.0) | 9 (20.9) | 11 (42.3) | Â |
C (1/2) | 38 (52.2) | 22 (48.8) | 16 (57.7) | 0.40 |
C1 | 33 (72.1) | 20 (44.2) | 13 (46.2) | Â |
C2 | 5 (7.2) | 2 (4.7) | 3 (11.5) | Â |